ArticleCell death & disease2026
α-ketoglutarate accumulation orchestrates immunosuppressive metabolic remodeling to drive cetuximab resistance in metastatic colorectal cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neddylation as a molecular integrator of metabolic dysfunction and endothelial dysfunction in type 2 diabetes.Acta pharmacologica Sinica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cetuximab resistance remains a major obstacle in the treatment of metastatic colorectal cancer (mCRC), highlighting the urgent need to identify synthetic lethal partners of EGFR. In this study, we observed glutamate dehydrogenase 1 (GDH1) accumulation in cetuximab-treated CRC samples. GDH1 depletion sensitized CRC cells to cetuximab and suppressed remodeling of the tumor immune microenvironment (TIME), as revealed by single-cell RNA sequencing. Mechanistically, cetuximab treatment induced substantial cytosolic accumulation of GDH1. Under normal conditions, EGFR directly phosphorylates cytosolic GDH1 at Y451, leading to HIP1R-mediated lysosomal degradation. Cetuximab, however, blocks GDH1-Y451 phosphorylation, thereby stabilizing GDH1 and increasing α-ketoglutarate (αKG) production. Elevated αKG enhances ALKBH5 activity to demethylate m6A modifications in the 3'UTR of NDUFA2, CXCL3, and SOS1 pre-mRNAs. This cascade coordinately rewires tumor cell metabolism and reprograms the TIME, while also amplifying KRAS-driven signaling to promote CRC liver metastasis. Importantly, combining cetuximab with the GDH1 activity inhibitor R162 curbed tumor metabolic adaptation, reversed TIME remodeling, and suppressed KRAS activation, thereby preventing immune escape and metastatic progression. Our findings unveil the EGFR/GDH1/αKG/ALKBH5 axis as a key modulator of cetuximab response and suggest that post-treatment monitoring of blood αKG may help identify patients who could benefit from GDH1 inhibition to augment immunotherapy and KRAS-targeted strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.